Tuesday | Wednesday | Thursday | Friday | Saturday
WEDNESDAY, DECEMBER 6, 2017
7:00 am - 5:15 pm Registration - Main Lobby  
     
7:00 am - 8:00 am Continental Breakfast - Hall 2  
     
8:00 am - 8:30 am WELCOME AND OPENING REMARKS – Hall 3
C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX
 
     
8:30 am - 9:00 am SABCS 40th Anniversary Award Lecture: Past and Future of Cancer Drug Development - Hall 3
Richard Pazdur, MD
US Food and Drug Administration
Silver Spring, MD
 
                            
9:00 am - 9:30 am PLENARY LECTURE 1 – Hall 3  
 

Potential of Radiation Therapy to Convert the Tumor into an In Situ Vaccine
Silvia C. Formenti, MD
Weill Cornell Medicine
New York, NY

 
     
9:30 am - 11:15 am

GENERAL SESSION 1 – Hall 3
Moderator: Sibylle Loibl, MD, PhD
German Breast Group
Neu-Isenburg, GERMANY

 
     
9:30 am GS1-01.  Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: an EBCTCG meta-analysis of 21,000 women in 16 randomised trials
 
                           Gray R, Bradley R, Braybrooke J, Davies C, Pan H, Peto R, Bliss J, Cameron D, Mackey J, Del Mastro L, Swain S, Untch M, Bergh J, Pritchard K, Norton L, for the EBCTCG. University of Oxford, Oxford, United Kingdom; Institute of Cancer Research, Sutton, United Kingdom; University of Edinburgh, Edinburgh, United Kingdom; University of Alberta, Edmonton, AB, Canada; National Cancer Research Institute, Genoa, Italy; Georgetown University, Washington, DC; HELIOS Klinikum Berlin-Buch, Berlin, Germany; Karolinska Institutet, Stockholm, Sweden; University of Toronto, Toronto, ON, Canada; Memorial Sloan Kettering Cancer Center, New York, NY.  
     
9:45 am

GS1-02. NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC)

 
                           Fehrenbacher L, Cecchini RS, Geyer CE, Rastogi P, Costantino JP, Atkins JN, Polikoff J, Boileau J-F, Provencher L, Stokoe C, Moore TD, Robidoux A, Borges V, Albain KS, Swain SM, Paik S, Mamounas EP, Wolmark N.  NSABP/NRG Oncology; Kaiser Permanente, Northern California; NRG Oncology; University of Pittsburgh; Virginia Commonwealth University, Massey Cancer Center; University of Pittsburgh Cancer Institute; SCOR - NCORP; Kaiser Permanente, San Diego California; Jewish General Hospital Segal Cancer Center, McGill University; CHU de Québec-Université Laval; Texas Oncology Plano East; The Columbus CCOP; Centre Hopitalier de l'Université de Montréal; University of Colorado; Loyola University Chicago Stritch School of Medicine; Georgetown Lombardi Comprehensive Cancer Center (current); Washington MedStar (where research was conducted); Yonsei University College of Medicine; UF Health; Allegheny Health Network Cancer Institute.
 
 
10:00 am GS1-03. Peri‐operative Aromatase Inhibitor treatment in determining or predicting Longterm Outcome in Early Breast Cancer –the POETIC* Trial (CRUK/07/015)  
                           Robertson JFR, Dowsett M, Bliss JM, Morden JP, Wilcox M, Evans A, Holcombe C, Horgan K, Kirwan C, Mallon E, Sibbering M, Skene A, Vidya R, Cheang M, Banerji J, Kilburn L, Dodson A, Smith I University of Nottingham, Royal Derby Hospital Centre, Derby, United Kingdom; Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, London, United Kingdom; The Institute of Cancer Research, Surrey, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom; Poole Hospital NHS Foundation Trust, Poole, United Kingdom; Royal Liverpool University Hospital, Liverpool, United Kingdom; Leeds Teaching Hospital, NHS Trust, Leeds, United Kingdom; University Hospital of South Manchester, Manchester, United Kingdom; Derby Teaching Hospital, NHS Trust, Derby, United Kingdom; Bournemouth and Christchurch Hospitals NHS Foundation Trust, Wolverhampton, United Kingdom; Birmingham University, Wolverhampton, United Kingdom
 
     
 10:15 am GS1-04. Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III trial  
  Sotiriou C, Rothé F, Maetens M, Fumagalli D, Brown DN, Salgado R, Bradbury I, Pusztai L, Harbeck N, Ignatiadis M; Sarp S, de la Pena L, de Azambuja E, Huober J, Nuciforo P, Baselga J, Piccart M, Loi S, Venet D. Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Belgium; Breast International Group - BIG aisbl, Belgium; Frontier Science Scotland, United Kingdom; Breast Medical Oncology Section, Yale Cancer Center, Yale School of Medicine, New Haven; University of Munich, Germany; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Novartis; SOLTI-Breast Cancer Research Group, Barcelona, Spain; Breast European Adjuvant Study Team, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Ulm, Germany; Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Memorial Sloan Kettering Cancer Center, New York; Peter MacCallum Cancer Center, Melbourne, Australia.  
     
10:30 am

GS1-05. Tandem duplicator phenotypes define 50% of triple negative breast cancers

 
  Liu ET, Menghi F, Barthel F, Yadav V, Tang M, Ji B, Carter G, Jonkers J, Verhaak R. The Jackson Laboratory for Genomic Medicine, Farmington, CT; MD Anderson Cancer Center, Houston, TX; Netherlands Cancer Institute, Amsterdam, Netherlands.
 
     
10:45 am GS1-06. Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: Phase III data from the SUCCESS A study
 
  Janni W, Friedl TWP, Fehm T, Müller V, Lichtenegger W, Blohmer J, Lorenz R, Forstbauer H, Bauer E, Fink V, Bekes I, Jückstock J, Schneeweiss A, Tesch H, Mahner S, Brucker SY, Heinrich G, Beckmann MW, Coleman R, Rack B.  University Hospital Ulm, Ulm, Germany; University Hospital Duesseldorf, Heinrich-Heine University, Duesseldorf, Germany; University Hamburg-Eppendorf, Hamburg, Germany; Charité University Hospital Campus Virchow, Berlin, Berlin, Germany;  Gynecologic Practice Dres Lorenz, Hecker, Wesche, Braunschweig, Germany; Hemato-Oncological Practice Dres Forstbauer and Ziske, Troisdorf, Germany; Ludwig-Maximilians-University Munich, Munich, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Onkologie Bethanien, Frankfurt, Germany; University Hospital Tübingen, Tübingen, Germany; Schwerpunktpraxis für Onkologische Gynäkologie, Fürstenwalde, Germany; University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Nuremberg, Germany; Sheffield Cancer Research Centre, Weston Park Hospital, University of Sheffield, Sheffield, United Kingdom  
     
11:00 am GS1-07.  Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results
 
                           Bardia A, Vahdat LT, Diamond J, Kalinsky K, O'Shaughnessy J, Moroose RL, Isakoff SJ, Tolaney SM, Santin AD, Abramson V, Shah NC, Govindan SV, Maliakal P, Sharkey RM, Wegener WA, Goldenberg DM, Mayer IA.  Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Weill Cornell Medicine, New York, NY; University of Colorado Cancer Center, Aurora, CO; Texas Oncology, Baylor University Medical Center, US Oncology, Dallas, TX; UF Health Cancer Center, Orlando, FL; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Yale University School of Medicine, New Haven, CT; Vanderbilt-Ingram Cancer Center, Nashville, TN; Columbia University-Herbert Irving Comprehensive Cancer Center, New York, NY; Immunomedics, Inc., Morris Plains, NJ.  
     
11:15 am - 12:00 pm WILLIAM L. MCGUIRE MEMORIAL LECTURE - Hall 3  
 

The Early Breast Cancer Trialists' Collaborative Group
Sir Richard Peto, FRS
University of Oxford
Oxford, UNITED KINGDOM

 
     
12:00 pm - 1:00 pm BREAK  
     
1:00 pm - 2:00 pm CLINICAL SCIENCE FORUM - Stars at Night Ballroom 1&2 - 3rd Level  
 

Controversies in the Adjuvant Treatment of ER+ Breast Cancer
Moderator: Matthew P. Goetz, MD
Mayo Clinic
Rochester, MN

Adjuvant endocrine therapy for premenopausal ER+ breast cancer
Prudence A. Francis, MBBS, B Med Sc, FRACP, MD
Peter MacCallum Cancer Centre
Melbourne, AUSTRALIA

Searching for the optimal duration of adjuvant endocrine therapy in breast cancer
Vered Stearns, MD
Johns Hopkins University
Baltimore, MD

 
     
1:00 pm - 2:00 pm BASIC SCIENCE FORUM 1 - Stars at Night Ballroom 3&4 - 3rd Level  
 

Targeting the Tumor Immune Microenvironment
Moderator: Xiang Zhang, PhD
Baylor College of Medicine
Houston, TX

Epigenetic therapy activates type 1 interferon signaling to reduce immunosuppression and tumor burden
Cynthia A. Zahnow, PhD
Johns Hopkins University
Baltimore, MD

Myeloid-derived suppressor cells: many facets of regulation of tumor progression
Dmitry I. Gabrilovich, MD, PhD
The Wistar Institute
Philadelphia, PA

 
  

  EDUCATIONAL SESSION - Hemisfair Ballroom 2&3 - 3rd Level  
Ex-vivo Modeling of Breast Cancer
Moderator: Carlos L. Arteaga, MD
UT Southwestern Medical Center
Dallas, TX

Genetic dissection of cancer development, therapy response and resistance in mouse models of breast cancer
Jos Jonkers, PhD
Netherlands Cancer Institute
Amsterdam, NETHERLANDS

A novel human derived organoid platform for breast cancer research
Oded Kopper, PhD
The Hubrecht Institute
Utrecht, NETHERLANDS

Breast cancer patient-derived xenografts as models for metastatic progression and therapeutic response
Alana L. Welm, PhD
University of Utah
Salt Lake City, UT

 
     
2:15 pm - 3:15 pm

SUSAN G. KOMEN® BRINKER AWARDS FOR SCIENTIFIC DISTINCTION LECTURES – Hall 3

 
  SUSAN G. KOMEN® BRINKER AWARD FOR SCIENTIFIC DISTINCTION IN BASIC SCIENCE 
The Development of Synthetic Lethal Treatments for Cancer
Alan Ashworth, PhD, FRS
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
 
  SUSAN G. KOMEN® BRINKER AWARD FOR SCIENTIFIC DISTINCTION IN CLINICAL RESEARCH 
Molecular Diversity of Human Breast Cancer: Biologic and Therapeutic Implications
Dennis J. Slamon, MD, PhD
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, CA
 
3:15 pm - 5:00 pm

GENERAL SESSION 2 – Hall 3
Moderator: Aleix Prat, MD, PhD
Hospital Clinic
Barcelona, SPAIN

 
3:15 pm GS2-01. Discovery  and characterization of an estrogen bound LncRNA in late-stage breast cancer  
                          

Maher CA, Silva-Fisher J, Eteleeb A, Tang C, Perou C, Reis-Filho JS, Mardis ER, Ellis MJ.  Washington University School of Medicine in St. Louis; The McDonnell Genome Institute; University of North Carolina at Chapel Hill; Memorial Sloan Kettering Cancer Center; Nationwide Children's Hospital, Institute for Genomic Medicine; Baylor College of Medicine in Houston.

 
     
3:30 pm GS2-02. Direct regulation of estrogen receptor-α (ER) transcriptional activity by NF1  
  Chang EC, Zheng Z, Philip L, Burcu C, Lei J, Singh P, Anurag M, Chan D, Li JD, Du XP, Shafaee MN, Banks K, Sacker S, Song W, Nguyen T, Cao J, Chen X, Haricharan S, Kavuri M, Kim B-J, Zhang B, Gutmann DH, Lanman RB, Foulds C, Ellis M.  Baylor College of Medicine, Houston, TX; Guardant Health, Inc., Redwood City, CA; Washington University School of Medicine, St. Louis, MO; The Academy of Medical Science of Zhengzhou University, Zhengzhou, Henan, China; Southwest Medical University, Luzhou, Sichuan, China.  
     
3:45 pm GS2-03. Highly recurrent transcriptional remodeling events in advanced endocrine resistant ER-positive breast cancers
 
  Priedigkeit N, Vareslija D, Basudan A, Watters RJ, Lucas PC, Davidson NE, Blohmer J-U, Denkert C, Machleidt A, Heppner BI, Brufsky AM, Oesterreich S, Young L, Lee AV. University of Pittsburgh, Pittsburgh, PA; Royal College of Surgeons in Ireland, Dublin, Ireland; Fred Hutchinson Cancer Research Center, University of  Washington, Seattle, WA; Charité  University Hospital, Berlin, Germany.  
     
4:00 pm  GS2-04. Discussant
Myles A. Brown, MD
Dana-Farber Cancer Institute
Boston, MA
 
     
4:15 pm GS2-05. First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial  
                           Tripathy D, Sohn J, Im S-A, Franke F, Bardia A, Harbeck N, Hurvitz S, Chow L, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Colleoni M, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu Y-S. The University of Texas MD Anderson Cancer Center, Houston, TX; Severance Hospital of Yonsei University Health System, Seoul, Republic of Korea; Seoul National University College of Medicine, Seoul, Republic of Korea; Hospital de Caridade de Ijui, CACON, Ijuí, Brazil; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Breast Center, University of Munich (LMU), Munich, Germany; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; Organisation for Oncology and Translational Research, Hong Kong; Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Institut Català d'Oncologia, Hospital Moisès Broggi, Barcelona, Spain; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Unità di Ricerca in Senologia Medica – Istituto Europeo di Oncologia, Milan, Italy; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; National Taiwan University Hospital, Taipei, Taiwan.  
     
4:30 pm GS2-06. Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/KEYNOTE-014) study
 
  Loi S, Giobbe-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, Andre F. International Breast Cancer Study Group and Breast International Group.   
     
4:45 pm GS2-07. MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer  
  Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, Makris A, Nemsadze G, Brunt AM, Kuemmel S, Ruiz Cabrero I, Perelló A, Kendall A, Brown J, Kristeleit H, Conibear J, Saura C, Grenier J, Máhr K, Schenker M, Sohn JH, Lee KS, Sarker S-J, Coetzee C, Mousa K, Cortes Castan J. Queen Mary University of London, United Kingdom; Praxis fuer Interdisziplinaere Onkologie, Germany; Derriford Hospital - Plymouth Hospitals NHS Trust, United Kingdom; Mount Vernon Cancer Centre - East and North Herts NHS Trust, United Kingdom; University Hospitals of North Midlands NHS Trust, United Kingdom; Keele University, United Kingdom; Kliniken - Essen - Mitte, Germany; Hospital Universitario Sant Joan De Reus, Spain; SOLTI, Spain; Great Western Hospitals NHS Foundation Trust, United Kingdom; Queen Elizabeth Hospital, Woolwich - South London Healthcare NHS Trust, United Kingdom; Institut Sainte Catherine, France; Sf. Nectarie Oncology Center SRL, Romania; Severance Hospital, Yonsei University Health System, Republic of Korea; National Cancer Center, Republic of Korea; Ramon Y Cajal University Hospital, Spain; Vall d'Hebron University Hospital, Spain; Kent Oncology Centre - Maidstone and Tunbridge Wells NHS Trust, United Kingdom; IPO Porto, Portugal; Nottingham University Hospitals NHS Trust, United Kingdom; Institute of Clinical Oncology, Georgia; Hospital Son Espases, Spain; Sheffield Teaching Hospitals NHS Foundation Trust, United Kingdom; Barts Health NHS Trust, United Kingdom; Zala County Hospital, Hungary.  
     
5:00 pm - 7:00 pm

Spotlight on Cancer Predisposition, Somatic Changes, and Genetic Testing – Stars at Night Ballroom 1&2 - 3rd Level

Chair: Rachel Schiff, PhD
Baylor College of Medicine
Houston, TX

Discussants:

Cancer Predisposition
Ephrat Levy-Lahad, MD
Shaare Zedeck Medical Center
Jerusalem, ISRAEL

Germline Genetic Testing
Julie Nangia, MD
Baylor College of Medicine
Houston, TX

Somatic Genetic Changes
Kornelia Polyak, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

 
                          
 
5:00 pm - 7:00 pm Spotlight on Innovations of SLN Mapping and Imaging - Stars at Night Ballroom 3&4 - 3rd Level
Chair: David A. Mankoff, MD, PhD
Perelman School of Medicine
Philadelphia, PA

Discussants:
SLN Mapping
Amit Goyal, MS, MD, FRCS
Royal Derby Hospital
Derby, UNITED KINGDOM

Breast Cancer Imaging: Predictive Markers and Response Assessment
Maxine S. Jochelson, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Advances in Breast Cancer Screening and Diagnosis
Sarah M. Friedewald, MD
Northwestern Medicine Feinberg School of Medicine
Chicago, IL
 
     
5:00 pm - 7:00 pm POSTER SESSION 1 & reception – Hall 1
 
     
 

Tumor Cell and Molecular Biology

Tumor Progression, Invasion and Metastasis
Metabolism and Breast Cancer
Signaling Pathways
Virology
Other

P1-01
P1-02
P1-03
P1-04
P1-05

     
 

Prognostic and Predictive Factors

Prognostic Factor Index Scores
Other

P1-06
P1-07

     
 

Treatment

Immunotherapy (Clinical)
Novel Targets and Targeted Agents
New Drugs and Treatment Strategies
Antiangiogenic Therapy (Adjuvant and Metastatic)
Antibody Based Regimens
Adjuvant Therapy
Advanced Therapy - Other
Adjuvant Therapy - Other
Bone Metastases
Brain Mets

P1-08
P1-09
P1-10
P1-11
P1-12
P1-13
P1-14
P1-15
P1-16
P1-17

     
  Ongoing Clinical Trials

Ongoing Trials - Immunotherapy
Ongoing Trials - Target PD-1
Ongoing Trials - HER2
Ongoing Trials - Endocrine Therapy
Ongoing Trials - Endocrine Therapy - AR
Ongoing Trials - Predictive Factors


OT1-01
OT1-02
OT1-03
OT1-04
OT1-05
OT1-06
     
7:30 pm - 10:00 pm

OPEN SATELLITE EVENT hosted by Dr. Neil Love and Research to Practice - Marriott Rivercenter, Salon E

Cases from the Community: Clinical Investigators Provide Their Perspectives on Emerging Research and Actual Patients with Breast Cancer 

For more information and to register for this event, please click on the link below:
http://www.researchtopractice.com/Meetings/SA2017


 
     
 
Tuesday | Wednesday | Thursday | Friday | Saturday
 

S1-04.

S1-04.